UroGen is a speculative biotech with revenue growing about 199% year over year and 59.5% upside to the analyst target, but it still burns cash, depends on two products and faces earnings in three days with insiders selling.
Thesis pillars
- Rapid Revenue Ramp↑Improving
- Cash Burn Narrowing→Stable
- Analyst Target Upside↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Mar 2, 2026
UroGen Pharma Ltd. (URGN) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Wait for pullback to $31.31. Weak momentum; also insider activity concern, recent C-suite change — blocks BUY_NOW at $32.72. Engine's entry $31.31 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Jelmyto and Zusduri; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).
UroGen Pharma is a commercial-stage biotechnology company developing non-surgical treatments for urothelial cancers using its proprietary RTGel sustained-release hydrogel technology. Its two FDA-approved products, Jelmyto for low-grade upper tract urothelial cancer and Zusduri... Read more
Wait for pullback to $31.31. Weak momentum; also insider activity concern, recent C-suite change — blocks BUY_NOW at $32.72. Engine's entry $31.31 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Jelmyto and Zusduri; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Score 6.2/10, moderate confidence.
Passes 4/8 gates (favorable risk/reward ratio, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 1d<=7d. Suitability: speculative.
About UroGen Pharma Ltd.
About UroGen Pharma Ltd.
UroGen Pharma sells two FDA-approved, RTGel-based mitomycin therapies in the United States: Jelmyto, approved in April 2020 for low-grade upper tract urothelial cancer, and Zusduri, approved in June 2025 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company reported net losses of $153.5 million in 2025 and held $120.5 million in cash and marketable securities at December 31, 2025, having accumulated deficits of $959.7 million since operations began in 2004.
Jelmyto reaches patients through agreements with national, regional, and local mixing pharmacies that prepare and dispense the admixture following a prescription, supported by a roughly 150-person customer-facing team of territory business managers, clinical nurse educators, and reimbursement specialists; Medicare covers Jelmyto under a permanent J-code, and the company says most commercial plans have coverage policies in place. UroGen has financed commercialization partly through debt: a February 2026 amended term loan facility with Pharmakon provides up to $250 million at a fixed 8.25% rate, refinancing $125 million outstanding under a prior facility, while a 2021 prepaid forward contract with RTW Investments entitles RTW to tiered payments on worldwide net sales of Jelmyto, Zusduri, and pipeline candidates UGN-103 and UGN-104, capped at an aggregate $300 million. Beyond its approved products, the pipeline includes UGN-501, an investigational oncolytic virus for immuno-uro-oncology.
Show full overview
UroGen's investment case rests on two products built on the same underlying technology: the 10-K states the company is 'highly dependent on the successful commercialization' of Jelmyto and Zusduri, both RTGel-based formulations of the same active ingredient, mitomycin. That shared chemistry means a single safety signal, manufacturing issue, or physician-adoption setback tied to mitomycin delivery could pressure both revenue streams simultaneously rather than diversifying risk the way a multi-mechanism portfolio would. The company's revenue-sharing obligations to RTW Investments, capped at $300 million and tied to combined net sales of both products, further concentrate financial exposure around the same technology platform succeeding commercially.
See also: Healthcare · Biotechnology
From UroGen Pharma Ltd.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-11-02Recent Developments — UroGen Pharma Ltd.
Latest news
- NEWS UroGen Pharma stock trades down 1.40% ahead of Q2 earnings webcast, UroGenPharma announces - Traders Union — Traders Union negative
- NEWS UroGen Pharma stock trades down 1.40% ahead of Q2 earnings webcast, UroGenPharma announces - tradersunion.com — tradersunion.com negative
- NEWS UroGen Pharma stock holds at $40.88 as UroGenPharma announces Q2 webcast date - Traders Union — Traders Union neutral
- NEWS UroGen Pharma stock holds at $40.88 as UroGenPharma announces Q2 webcast date - tradersunion.com — tradersunion.com neutral
- NEWS Oppenheimer reiterates Outperform on UroGen Pharma stock at $60 By Investing.com - Investing.com Nigeria — Investing.com Nigeria positive
Generated 2026-11-02T11:38:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductJelmyto and Zusduri10-K Item 1A: 'We are highly dependent on the successful commercialization of our approved products, Jelmyto and Zusduri.'
Material Events(8-K, last 90d)
- 2026-06-23Item 3.03LOWAt the June 22, 2026 Annual Meeting, shareholders approved an amendment and restatement of the company's Articles of Association tying shareholder-proposal eligibility to Israeli Companies Law requirements.SEC filing →
- 2026-06-23Item 5.02LOWAt the same Annual Meeting, shareholders approved amendments to compensatory arrangements; the filing text describing the specific changes was truncated in the source document.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $31.31. Weak momentum; also insider activity concern, recent C-suite change — blocks BUY_NOW at $32.72. Engine's entry $31.31 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Jelmyto and Zusduri; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Target $52.20 (+59.5%), stop $29.12 (−12.4%), A.R:R 5.8:1. Score 6.2/10, moderate confidence.
Take-profit target: $52.20 (+59.5% upside). Target $52.20 (+59.5%), stop $29.12 (−12.4%), A.R:R 5.8:1. Stop-loss: $29.12.
Concentration risk — Product: Jelmyto and Zusduri; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7); Negative momentum.
UroGen Pharma Ltd. trades at a P/E of N/A (forward 12.6). TrendMatrix value score: 7.4/10. Verdict: Buy (Wait for Entry).
13 analysts cover URGN with a consensus score of 4.4/5. Average price target: $60.
What does UroGen Pharma Ltd. do?UroGen Pharma is a commercial-stage biotechnology company developing non-surgical treatments for urothelial cancers...
UroGen Pharma is a commercial-stage biotechnology company developing non-surgical treatments for urothelial cancers using its proprietary RTGel sustained-release hydrogel technology. Its two FDA-approved products, Jelmyto for low-grade upper tract urothelial cancer and Zusduri for recurrent low-grade intermediate-risk bladder cancer, both formulate the chemotherapy drug mitomycin, and the company's prospects are highly dependent on their continued commercial success.